Eli Lilly’s experimental breast cancer drug, abemaciclib, has been granted a priority review by US regulators for two indications, and is now on track to be filed in Europe later in 2017.
NICE are backing controlled use of targeted breast cancer radiotherapy treatment alongside further research. The National Institute for Health and Care Excellence recently published draft guidance recommending the Intrabeam Radiotherapy System (Carl Zeiss UK) as an option for patients with early forms of breast cancer.
Novartis has announced that the FDA has granted a breakthrough therapy designation to LEE011 (ribociclib) as first line treatment in HR+/HER2- advanced breast cancer.
The Clinical Professionals Group, Europe’s leading independent pharmaceutical staffing company, raised over £200 for Breast Cancer Care on Friday 18th October, as part of Breast Cancer Awareness Month. The offices took part in a variety of ‘pink’ themed activities throughout the day, including a pink themed quiz and sponsored pink nail painting for some of
Draft guidance issued today by the regulatory body, NICE (National Institute for Health and Care Excellence), has confirmed that the NHS in England and Wales has been advised not to routinely provide Roche’s Perjeta (pertuzumab). Perjeta was submitted as a treatment for a type of advanced breast cancer, but has been found not to represent value
Novartis announced on Friday that they have received approval from US regulators for Afinitor as a treatment for advanced breast cancer. The US Food and Drug Administration (FDA) have given the thumbs up to Afinitor (everolimus) for use with Pfizer’s Aromasin (exemestane) to treat certain postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer. The
In final draft guidance given yesterday, the National Institute for Health and Clinical Excellence (NICE) announced that they are not recommending Eisai’s Halaven (eribulin) for the treatment of locally-advanced or metastatic breast cancer in people whose disease has progressed after at least two chemotherapeutic regimens for advanced disease. Although the evidence shown to NICE’s independent
England and Wales’ cost watchdog, NICE, yesterday reiterated their assessment that AstraZeneca’s breast cancer drug Faslodex does not represent good use of NHS funds and has not been proven to be better than current treatments. The National Institute for Health and Clinical Excellence (NICE) has published their final appraisal determination, saying that they do not
Swiss pharmaceutical company, Roche, yesterday announced that the Phase III HannaH study demonstrated comparable efficacy of a new, investigational subcutaneous formulation of Herceptin (trastuzumab) to the standard intravenous infusion of Herceptin in women with HER2-positive early breast cancer. HannaH is a Phase III, open-label study consisting of 596 women with HER2 positive early breast cancer.